NAVB was the most shorted stock on the AMEX the end of February and the FDA approval of their Lymphoseek caught everyone by surprise since it was six weeks early. It will take a few days for the short manipulation to work itself out before the share price starts rising. Earnings from Lymphoseek will start coming in Q2 with a +$1 billion potential in earnings at 50% market penetration and not counting other future approvals for use of Lymphoseek in other kinds of cancers other than breast and melanoma. Those trials are currently underway for head and neck cancer and prostate cancer. I took advantage of the drop from the bear raid to add to my holdings. I'm still in the green since I began accumulating NABB (which was then NEOP) well below $2 a share. With patience NAVB will reach the analyst targets of $6-9 a share, probably by the end of the year after Q2 and Q3 results are released.